Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell lines

Tumour Biol. 1997;18(4):232-40. doi: 10.1159/000218036.

Abstract

Two ovarian cancer cell lines, OVC432 and the newly established CVU4I, were used to study the effect of Taxal on cell growth and simultaneous CA 125 antigen expression. Growth of both cell lines was effectively inhibited by drug concentrations of 0.1 microM and higher. Complete inhibition of cell growth may result from high concentrations of Cremophor EL present in the Taxol formulation. Immunohistochemical analysis demonstrated that both cell lines retained the CA 125 expression on the cell surface during exposure to paclitaxel. This was reflected in a constant statistically significant correlation between cell numbers and CA 125 concentrations found in cell lysates. CA 125 levels in the culture medium showed a significant relation to cell numbers and, consequently, to the response of the cell line to the administered anticancer drug. It may be concluded from this study that CA 125 seems to be a reliable tumor marker in monitoring tumor response during paclitaxel treatment.

MeSH terms

  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • CA-125 Antigen / metabolism*
  • Cell Count / drug effects
  • Cystadenocarcinoma, Serous / drug therapy
  • Cystadenocarcinoma, Serous / metabolism*
  • Female
  • Glycerol / analogs & derivatives
  • Glycerol / pharmacology
  • Humans
  • Immunohistochemistry
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / metabolism*
  • Paclitaxel / pharmacology*
  • Paclitaxel / therapeutic use
  • Pharmaceutical Vehicles / pharmacology
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents, Phytogenic
  • CA-125 Antigen
  • Pharmaceutical Vehicles
  • cremophor EL
  • Paclitaxel
  • Glycerol